Patents by Inventor Yinon Ben-Neriah

Yinon Ben-Neriah has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20050171005
    Abstract: The present invention provides modulators of ?-catenin phosphorylation. More specifically, the present invention provides inhibitors and enhancers of ?-catenin Serine 45 (S45) phosphorylation. Examples of inhibitors provided by the invention are the proteins Dishevelled (Dvl), Wnt, phosphatase PP2A and CKI7. Examples of enhancers of beta-catenin phosphorylation are phosphatase inhibitors and proteins that promote ?-catenin acetylation, like FRAT1. In addition, the present invention provides compositions and uses of the modulators of the invention, specifically for the treatment of cancer, as well as a method for screening such modulators.
    Type: Application
    Filed: October 25, 2004
    Publication date: August 4, 2005
    Inventors: Yinon Ben-Neriah, Irit Alkalay, Sharon Amit, Yaara Birman, Ada Hatzubai
  • Patent number: 6905836
    Abstract: Compounds that inhibit ubiquitin-mediated proteolysis of phosphorylated I?B by interfering, directly or indirectly, with the ability of ?-TrCP/E3RS to engage in protein-protein association involving hnRNP-U, are useful as drugs for treating conditions associated with NF-?B activation. Cellular and non-cellular screening methods for identifying such compounds are based on monitoring the association/dissociation of ?-TrCP/E3RS.
    Type: Grant
    Filed: February 10, 2003
    Date of Patent: June 14, 2005
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem
    Inventors: Yinon Ben-Neriah, Irit Alkalay-Snir, Ada Hatzubai, Etti Ben Shushan, Matti Davis, Avraham Yaron
  • Publication number: 20040203098
    Abstract: Compositions and methods for modulating the activation of nuclear factor &kgr;B (NF-&kgr;B) are provided. The compositions comprise one or more agents that modulate ubiquitination of phosphorylated I&kgr;B&agr; and/or I&kgr;B&bgr;. Such compositions may be used for treating diseases associated with NF-&kgr;B activation. Modulating agents include human E3 ubiquitin ligases, antibodies thereto and variants thereof, as well as related proteins.
    Type: Application
    Filed: September 19, 2003
    Publication date: October 14, 2004
    Inventors: Anthony M. Manning, Frank Mercurio, Sharon Amit, Yinon Ben-Neriah, Matti Davis, Ada Hatzubai, Avraham Yaron, Irit Alkalay, Aaron Ciechanover
  • Publication number: 20040014026
    Abstract: Compounds that inhibit ubiquitin-mediated proteolysis of phosphorylated I&kgr;B by interfering, directly or indirectly, with the ability of &bgr;-TrCP/E3RS to engage in protein-protein association involving hnRNP-U, are useful as drugs for treating conditions associated with NF-&kgr;B activation. Cellular and non-cellular screening methods for identifying such compounds are based on monitoring the association/dissociation of &bgr;-TrCP/IE3RS.
    Type: Application
    Filed: February 10, 2003
    Publication date: January 22, 2004
    Inventors: Yinon Ben-Neriah, Irit Alkalay-Snir, Ada Hatzubai, Etti Ben Shushan, Matti Davis, Avraham Yaron
  • Patent number: 6656713
    Abstract: Compositions and methods for modulating the activation of nuclear factor &kgr;B (NF-&kgr;B) are provided. The compositions comprise one or more agents that modulate ubiquitination of phosphorylated I&kgr;B&agr; and/or I&kgr;B&bgr;. Such compositions may be used for treating diseases associated with NF-&kgr;B activation. Modulating agents include human E3 ubiquitin ligases, antibodies thereto and variants thereof, as well as related proteins.
    Type: Grant
    Filed: April 9, 2001
    Date of Patent: December 2, 2003
    Assignee: Signal Pharmaceuticals, Inc.
    Inventors: Anthony M. Manning, Frank Mercurio, Sharon Amit, Yinon Ben-Neriah, Matti Davis, Ada Hatzubai, Avraham Yaron, Irit Alkalay, Aaron Ciechanover
  • Publication number: 20030166587
    Abstract: Compositions and methods for modulating the activation of nuclear factor &kgr;B (NF-&kgr;B) are provided. The compositions comprise one or more agents that modulate ubiquitination of phosphorylated I&kgr;B&agr; and/or I&kgr;B&bgr;. Such compositions may be used for treating diseases associated with NF-&kgr;B activation. Modulating agents include human E3 ubiquitin ligases, antibodies thereto and variants thereof, as well as related proteins.
    Type: Application
    Filed: April 9, 2001
    Publication date: September 4, 2003
    Inventors: Anthony M. Manning, Frank Mercurio, Sharon Amit, Yinon Ben-Neriah, Matti Davis, Ada Hatzubai, Avraham Yaron, Irit Alkalay, Aaron Ciechanover
  • Patent number: 5932425
    Abstract: Compositions and methods for modulating the activation of nuclear factor .kappa.B (NF-.kappa.B) are provided. The compositions comprise one or more agents that modulate ubiquitination of phosphorylated I.kappa.B.alpha. and/or I.kappa.B.beta.. Such compositions may be used for treating diseases associated with NF-.kappa.B activation. Modulating agents include peptides that comprise a recognition domain for E3 ubiquitin ligase.
    Type: Grant
    Filed: February 18, 1997
    Date of Patent: August 3, 1999
    Assignees: Signal Pharmaceuticals, Inc., Yissum Research Development Company of the Hebrew University of Jerusalem
    Inventors: Irit Alkalay, Yinon Ben-Neriah, Aaron Ciechanover, Anthony Manning, Frank Mercurio, Avraham Yaron